Welcome to our dedicated page for Aspira Women`s Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women`s Health stock.
Aspira Women's Health Inc. develops and commercializes noninvasive, AI-powered blood tests used in gynecologic disease diagnostics and disease management. Company news centers on OvaSuite, which includes OvaWatch and Ova1Plus, and on Ova1 and Overa as FDA-cleared components used to assess ovarian malignancy risk in women with adnexal masses.
Recurring updates also cover ENDOinform, a blood draw-based multi-omics test in development for endometriosis using protein and microRNA biomarkers with patient-specific data. Other company developments include financial results, ARPA-H program milestones, OTCQB trading status, equity and capital actions, and board or governance changes.
Aspira Women’s Health, Inc. (AWH) is set to report its third-quarter financial results for the period ending September 30, 2020, on November 12, 2020, after market close. An investor conference call will follow at 4:30 p.m. ET. The company focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment and pelvic disease management. Aspira is positioned to address ethnic disparities in health outcomes through its product portfolio, including OVA1 plus and ASPIRA GenetiX testing.
Aspira Women’s Health Inc. (Nasdaq: AWH) announces a significant expansion of network access for its OVA1® and ASPIRA GenetiX® testing, now serving approximately 3.3 million members of Anthem BlueCross BlueShield of Georgia. This partnership allows Aspira to reach nearly 30% of Georgia’s population, enhancing access to crucial ovarian cancer risk assessment tools. The company is committed to addressing ethnic disparities in ovarian cancer, focusing on delivering innovative testing solutions for women across various demographics.
Aspira Women’s Health, Inc. (Nasdaq: AWH) has been invited to present at the MicroCap Rodeo Best Ideas Bowl, occurring virtually from October 13-16, 2020. The company’s presentation is scheduled for October 14 from 11:30-11:55 am EST, and will be available for live streaming and replay. Aspira focuses on innovative testing solutions for women’s health, specifically addressing ovarian cancer risk assessment and pelvic diseases. Interested parties can register for the webcast or one-on-one meetings via the provided links.
Aspira Women’s Health (Nasdaq: AWH) will host a key opinion leader (KOL) call on September 25, 2020, at 12:00 PM ET, to discuss ovarian cancer diagnostics and their innovation pipeline. KOLs Dr. Christopher Bryant and Dr. Gerard P. Reilly will present insights on current diagnostics, treatment options, and AWH’s clinical studies. The management team will also share details on their rebranding initiatives and products like OVA1 plus. Interested parties can register.